Oncodesign Services (ODS) and Veritas In Silico (VIS) announced that they have entered into a Memorandum of Understanding (MOU) to respond to the needs of pharmaceutical companies seeking to develop innovative small molecule drugs targeting messenger RNA (mRNA).

The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets. There is an increasing number of biotechs elaborated in this field, yet it hasn’t met the wide-ranging needs of pharmaceutical companies seeking to commit to developing mRNA-targeted small molecule drugs.

VIS, as a pathfinder in mRNA-targeted drug discovery, has been paving the way for realizing mRNA-targeted small molecule drugs with its proprietary drug discovery platform, ibVIS, consisting of computational target identification of any given mRNA, robust and quantitative high throughput screening, and various drug discovery technologies fully optimized for mRNA targets.

ODS, as a world leading CRO and a pioneer in translational medicine, offers a full spectrum of integrated drug discovery services from the conception and design of molecules, through efficient and intelligent optimization and evaluation, to sustain preclinical candidate selection and nomination.

The business cooperation between ODS and VIS enables clients in the pharmaceutical industry to leverage the benefits of VIS’s ibVIS® platform with the support of ODS’s drug discovery and development expertise in major therapeutic areas for the discovery of new drug candidates of mRNA-targeted small molecules.